Abstract
To evaluate the possible role of central free amino compounds in pediatric opsoclonus-myoclonus
syndrome (OMS), 21 cerebrospinal fluid (CSF) amino compounds were measured by an amino
acid analyzer or mass spectroscopy in 74 anesthetized children, 54 with OMS and 20
age-matched neurological controls. In OMS, only phosphoethanolamine was increased
compared to controls; OMS severity and duration had significant converse effects on
alanine and phosphoethanolamine. In contrast, corticotropin (ACTH) treatment was associated
with increased alanine and phenylalanine, and decreased taurine compared to controls
and untreated OMS, and increased glutamine, lysine, ornithine, and tyrosine compared
to untreated OMS. Other than low taurine, these effects were not found with corticosteroid
treatment, and non-steroidogenic immunotherapy had no effect. The ACTH dose-association
was most apparent for alanine and phosphoethanolamine, but lysine and ornithine were
also higher in the high-dose ACTH group. There were no significant disease- or treatment-associated
perturbations in GABA, glycine, or other amino acids. These data suggest a unique
pattern of ACTH effects on non-neurotransmitter CSF amino compounds, for the most
part not shared by steroids.
Key words
paraneoplastic syndrome - immunotherapy - ataxia - dancing eyes - ACTH - neuroblastoma
References
1
Airaksinen EM, Leino E.
Decrease of GABA in the cerebrospinal fluid of patients with progressive myoclonus
epilepsy and its correlation with the decrease of 5H1AA and HVA.
Acta Neurol Scand.
1982;
66
666-672
2
Crawford PM, Lloyd KG, Chadwick DW.
CSF gradients for amino acid neurotransmitters.
J Neurol Neurosurg Psychiatry.
1988;
51
1193-1200
3
Dahlin M, Elfving A, Ungerstedt U. et al .
The ketogenic diet influences the levels of excitatory and inhibitory amino acids
in the CSF in children with refractory epilepsy.
Epilepsy Res.
2005;
64
115-125
4
Eriksson AS, O’Connor WT.
Analysis of CSF amino acids in young patients with generalized refractory epilepsy
during an add-on study with lamotrigine.
Epilepsy Res.
1999;
34
75-83
5
Faull KF, DoAmaral JR, Berger PA. et al .
Mass spectrometric identification and selected ion monitoring quantitation of γ-aminobutyric
acid (GABA) in human lumbar cerebrospinal fluid.
J Neurochem.
1978;
31
1119-1122
6
Gerrits GP, Trijbels FJ, Monnens LA. et al .
Reference values for amino acids in cerebrospinal fluid of children determined using
ion-exchange chromatography with fluorimetric detection.
Clin Chim Acta.
1989;
182
271-280
7
Gillessen T, Budd SL, Lipton SA.
Excitatory amino acid neurotoxicity.
Adv Exp Med Biol.
2002;
513
3-40
8
Hagberg H, Thornberg E, Blennow M. et al .
Excitatory amino acids in the cerebrospinal fluid of asphyxiated infants: relationship
to hypoxic-ischemic encephalopathy.
Acta Paediatr.
1993;
82
925-929
9
Hara M, Kai Y, Ikemoto Y.
Propofol activates GABAA receptor-chloride ionophore complex in dissociated hippocampal pyramidal neurons
of the rat.
Anesthesiology.
1993;
79
781-788
10
Heyes MP, Saito K, Crowley JS. et al .
Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory
neurologic disease.
Brain.
1992;
115
1249-1273
11
Horikoshi T, Asanuma A, Yanagisawa K.
Taurine and β-alanine act both on GABA and glycine receptors in Xenopus oocyte injected
with mouse brain messenger RNA.
Mol Brain Res.
1988;
10
83-92
12
Kaakkola S, Marnela KM, Oja SS. et al .
Leukocyte glutamate dehydrogenase and CSF amino acids in late onset ataxias.
Acta Neurol Scand.
1990;
82
225-229
13
Kinsbourne M.
Myoclonic encephalopathy of infants.
J Neurol Neurosurg Psychiatry.
1962;
25
221-276
14
Klein A, Schmitt B, Boltshauser E.
Long-term outcome of ten children with opsoclonus-myoclonus syndrome.
Eur J Pediatr.
2007;
166
359-363
15
Kornhuber ME, Kornhuber J, Kornhuber AW. et al .
Positive correlation between contamination by blood and amino acid levels in cerebrospinal
fluid of the rat.
Neurosci Lett.
1986;
69
212-215
16
Lee PLY, Slocum RH.
A high-resolution method for amino acid analysis of physiologic fluids containing
mixed disulfides.
Clin Chem.
1988;
34
719-723
17
Levine J, Panchalingam K, Rapoport A. et al .
Increased cerebrospinal fluid glutamine levels in depressed patients.
Biol Psychiatry.
2000;
47
586-593
18
Loscher W, Siemes H.
Cerebrospinal fluid gamma-aminobutynic acid levels in children with different types
of epilepsy: effect of anticonvulsant treatment.
Epilepsia.
1985;
26
314-319
19
Mally J, Szalai G, Stone TW.
Changes in the concentration of amino acids in serum and cerebrospinal fluid of patients
with Parkinson's disease.
J Neurol Sci.
1997;
151
159-162
20
MacGale EHF, Pye IF, Stonier C. et al .
Studies of the inter-relationship between cerebrospinal fluid and plasma amino acid
concentrations in normal individuals.
J Neurochem.
1977;
29
291-297
21
Nicoli F, Vion-Dury J, Confort-Gouny S. et al .
Cerebrospinal fluid metabolic profiles in multiple sclerosis and degenerative dementias
obtained by high resolution proton magnetic resonance spectroscopy.
C R Acad Sci III.
1996;
319
623-631
22 Vivian ES.
Amino acid analysis. In: Physician's Guide to the Labora-tory Diagnosis of Metabolic
Diseases . 2nd edition, (Blau N, Duran M, Blaskovics ME, Gibson KM, eds.) Springer Verlag,
New York 2003
23
Pranzatelli MR.
On the molecular mechanism of adrenocorticotrophic hormone: neurotransmitters and
receptors.
Exp Neurol.
1994;
125
142-161
24
Pranzatelli MR.
The pharmacology of antimyoclonic drugs.
Clin Neurosci.
1996;
3
246-252
25
Pranzatelli MR.
The immunopharmacology of the opsoclonus-myoclonus syndrome.
Clin Neuropharmacol.
1996;
19
1-47
26 Pranzatelli MR. Opsoclonus-myoclonus-ataxia. In: Fernandez-Alvarez E, Arzimanoglou
A, Tolosa E, eds,
Pediatric Movement Disorders . John Libbey Eurotext Limited, Montrouge, France 2005: 121-136
27
Pranzatelli MR, Huang YY, Tate E. et al .
Monoaminergic effects of high-dose corticotropin in corticotropin-responsive pediatric
opsoclonus-myoclonus.
Mov Disord.
1998;
13
522-528
28
Pranzatelli MR, Tate ED, Galvan I. et al .
A controlled pilot study of piracetam for pediatric opsoclonus-myoclonus.
Clin Neuropharmacol.
2001;
24
352-357
29
Pranzatelli MR, Travelstead AL, Tate ED. et al .
B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes.
Neurology.
2004;
62
1526-1532
30
Rating D, Siemes H, Loscher W.
Low CSF GABA concentration with febrile convulsions, untreated epilepsy, and meningitis.
J Neurol.
1983;
230
217-225
31
Ross BM, Moszczynska A, Blusztajn JK. et al .
Phospholipid biosynthetic enzymes in human brain.
Lipids.
1997;
32
351-358
32
Rothrock JF, Mar KR, Yaksh TL. et al .
Cerebrospinal fluid analyses in migraine patients and controls.
Cephalalgia.
1995;
15
489-493
33
Schaff JM, Teelken AW, Muskiet FAJ. et al .
The specific and sensitive determination of gamma aminobutyric acid in CSF and brain
tissue by gas chromatography mass spectrometry.
J Neurosci Meth.
1985;
13
257-265
34
Shen EY, Lai YJ, Ho CS. et al .
Excitatory and inhibitory amino acid levels in the cerebrospinal fluids of children
with neurological disorders.
Acta Paediatr Taiwan.
1999;
40
65-69
35
Smith I, White PF, Nathanson M. et al .
Propofol: An update on its clinical use.
Anesthesiology.
1994;
81
1005
36
Smith SV, Forman DT.
Laboratory analysis of cerebrospinal fluid.
Clin Lab Sci.
1994;
7
32-38
37
Solomon GE, Chutorian AM.
Opsoclonus and occult neuroblastoma.
N Engl J Med.
1968;
279
475-477
38
Stover JF, Pleines UE, Morganti-Kossmann MC. et al .
Neurotransmitters in cerebrospinal fluid reflect pathological activity.
Eur J Clin Invest.
1997;
27
1038-1043
39
Takahashi K.
Studies on free amino acid patterns in cerebrospinal fluid of children. Part 1. The
individuality of the free amino acid patterns in cerebrospinal fluid.
Acta Paediatr Jpn.
1978;
20
11-23
40
Tate ED, Pranzatelli MR, Huang Yy. et al .
An innovative approach to problem of sedating children with opsoclonus-myoclonus syndrome:
effects on myoclonus and CSF monoamine metabolites.
Ann Neurol.
1994;
36
A609
41
Tatro JB.
Melanotropin receptors in the brain are differentially distributed and recognize both
corticotropin and alpha-melanocyte stimulating hormone.
Brain Res.
1990;
536
124-132
42 Hemelrijck J Van, White PF. Nonopioid intravenous anesthesia. In: Barash PG, Cullen
BF, Stoelting RK, eds,
Clinical Anesthesia . Lippincott-Raven Publishers, Philadelphia 1996: 311-327
43
Xiang J, Ennis SR, Abdelkarim GE. et al .
Glutamine transport at the blood-brain and blood-cerebrospinal fluid barriers.
Neurochem Int.
2003;
43
279-288
Correspondence
Prof. M. R. Pranzatelli
National Pediatric Myoclonus Center
Southern Illinois University School of Medicine
PO Box 19643
Springfield
IL 62794-9643
USA
Phone: +1/217/545 76 35
Fax: +1/217/545 19 03
Email: mpranzatelli@siumed.edu